Aurinia Pharmaceuticals Q3 2026 Results: Net Income $31.7M, Up 0.5% YoY
Aurinia Pharmaceuticals reported a significant increase in net income to $103.5 million for the nine months ended September 30, 2026, compared to $76.4 million in the prior year period, driven by a 19% growth in total revenue. The company maintained a strong liquidity position with $486.9 million in cash and short-term investments while continuing its share repurchase program.
- Key figure
- Net income $31.7M · +0.5% YoY